Europe Anthrax Vaccine Market industry research report 2031
[Hyderabad, June 12th, 2025] The Europe anthrax vaccine market has been growing steadily, backed by increasing concerns around biological warfare, the emergence of zoonotic diseases, and stringent veterinary disease control policies. Anthrax, a highly lethal disease caused by Bacillus anthracis, continues to pose a threat both to human and animal populations. European nations, particularly those in Eastern and Central Europe where anthrax remains endemic in certain rural areas, have maintained a consistent demand for vaccines. This demand is driven by the dual need to protect livestock populations and to maintain bio-preparedness in light of bioterrorism threats.
Request Sample @ https://clearviewmarketinsights.com/report-details/europe-anthrax-vaccine-market/
Market Size
As of 2023, the Europe anthrax vaccine market was valued at approximately USD
2.4 billion. Countries like Germany, France, the United Kingdom, and Poland are
the leading consumers due to their strong public health systems, advanced
veterinary infrastructure, and government-funded biosecurity programs. The
market also benefits from the European Union’s common framework on animal
disease control and preparedness against biological threats.
Market Size and Forecast
The market is projected to grow at a compound annual growth rate (CAGR) of
around 5.2% during the forecast period from 2024 to 2030, reaching nearly USD
3.5 billion by 2030. This growth is driven by increasing veterinary vaccine
mandates, modernization of stockpile facilities, and improved awareness of
biohazards. The livestock segment is expected to maintain dominance, but
human-use vaccines are witnessing growing interest amid rising biodefense
allocations in national budgets.
Competitive Landscape
The competitive landscape in Europe is moderately consolidated, with several
multinational and regional players active. Key manufacturers include Emergent
BioSolutions, Valneva SE (France), GSK, Bavarian Nordic,
and Bioveta (Czech Republic). These firms supply both human and
veterinary anthrax vaccines, with Emergent BioSolutions leading in the defense
segment due to its U.S. and European government contracts. Partnerships with
public health authorities, contract manufacturing, and investments in
next-generation vaccine R&D define the competitive dynamics.
Detailed Market Segmentation
The market can be segmented by:
- Vaccine Type: Cell-free PA
vaccines, Live-attenuated vaccines, Inactivated vaccines
- Application: Human health
(military, laboratory, and occupational use), Veterinary health (cattle,
sheep, goats)
- Distribution Channel: Government
procurement, Veterinary hospitals, Pharmacies
- End User: Military & defense,
General public, Agricultural and livestock sector
- Country: Germany, France, UK,
Italy, Spain, Rest of Europe
Market Challenges
Challenges include high R&D costs, stringent regulatory approvals, limited
awareness in the general public, and fragmented demand due to sporadic
outbreaks. Additionally, maintaining long-term contracts with low-demand
profiles makes scalability difficult for smaller manufacturers.
Primary Market Drivers
Key drivers include increasing government stockpiling, growing livestock
disease management programs, rising biosecurity awareness, and EU support for
epidemic prevention. Military demand, particularly in NATO-aligned countries,
also supports sustained investment in anthrax vaccine infrastructure.
Technology & Innovation
Innovation is focused on recombinant DNA-based vaccines, improved adjuvant
formulations, needle-free delivery mechanisms, and vaccines with longer
shelf-life for stockpile viability. Companies are also leveraging mRNA and
vector-based platforms for faster response to biothreats.
Regulatory Environment
The market is regulated by the European Medicines Agency (EMA) for human
vaccines and European Food Safety Authority (EFSA) for veterinary
products. Compliance with GMP and EU-wide harmonization of biosecurity
standards ensures product quality and public trust. New regulatory pathways
under the EU Civil Protection Mechanism may further streamline emergency
authorizations.
Recent Developments (Q4 2023
– Q2 2025)
Notable developments include:
- Expansion of Valneva’s anthrax vaccine R&D pipeline in France
- EU funding support for livestock vaccine distribution in
Eastern Europe
- EMA fast-tracking review of new-generation recombinant vaccines
- Trials of thermostable anthrax vaccines in collaboration with
military research institutes in Germany and the UK
Strategic Outlook
Looking forward, the Europe anthrax vaccine market is expected to expand
through defense sector demand, livestock protection mandates, and pan-EU
stockpiling programs. Strategic partnerships between governments and biotech
firms will be crucial in achieving rapid deployment capabilities. Companies
focusing on dual-use (human and veterinary) vaccine platforms and adaptable
cold chain logistics are poised for long-term success.
For more insights, visit https://clearviewmarketinsights.com/
About Clearview Market Insights:
Clearview Market Insights is a leading
market research and consulting firm providing in-depth industry analysis and
strategic recommendations for businesses worldwide.
Media contact:
Bhavani K
Marketing and Sales Head
ClearView Market Insights
Mail: sales@clearviewmarketinsights.com
Phone: +1 917-993-7369
Comments
Post a Comment